Clinical effects of whole-body hyperthermia in adnanced malignancy.
Fifty-one patients in the terminal stages of cancer have been treated with whole-body hyperthermia either alone (38 cases) or in combination with chemotherapy (13 cases). Altogether 227 treatment sessions were held averaging four hours each. The most sensitive tumours were those of the gastrointestinal tract and sarcomas. Breast and genitourinary tumours did not respond, and lung tumours and melanomas were only partially responsive. Major complications were remarkably few.
D000328:Adult; D001831:Body Temperature; D001943:Breast Neoplasms / Q000628:therapy; D002648:Child; D003110:Colonic Neoplasms / Q000628:therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D005770:Gastrointestinal Neoplasms / Q000628:therapy; D006801:Humans; D006979:Hyperthermia, Induced; D007275:Injections, Intravenous; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy / Q000628:therapy; D013997:Time Factors; D014750:Vincristine / Q000627:therapeutic use
D014750:Vincristine; D003520:Cyclophosphamide; D008558:Melphalan; D005472:Fluorouracil